Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
12:56pm, Thursday, 25'th Sep 2025
AstraZeneca stock is up 15% so far in 2025 as blockbuster drugs and a robust oncology portfolio fuel growth despite looming headwinds.
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
12:21pm, Thursday, 25'th Sep 2025
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
10:46am, Thursday, 25'th Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
08:45am, Thursday, 25'th Sep 2025
Even with Trump's looming threats to impose tariffs on pharma imports, the performance of AstraZeneca's cardiovascular and oncology franchises continues to impress me. So, sales of Truqap, which conti
Here's Why Astrazeneca (AZN) is a Strong Value Stock
10:41am, Wednesday, 24'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
01:01pm, Tuesday, 23'rd Sep 2025
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
02:20pm, Monday, 22'nd Sep 2025
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
08:00am, Monday, 22'nd Sep 2025
BOSTON , Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (L
Bloomberg Dividend Watchlist's 4 Ideal 'Safer' September Sizzlers
03:38am, Saturday, 20'th Sep 2025
Bloomberg Intelligence highlights 50 Companies to Watch for 2025, focusing on catalysts like leadership changes, M&A, and sector trends such as AI and EVs. Dogcatcher analysis identifies 13 dividend-p
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
07:16pm, Friday, 19'th Sep 2025
Astrazeneca (AZN) closed at $76.28 in the latest trading session, marking a -1.03% move from the prior day.
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
09:30am, Friday, 19'th Sep 2025
AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and efficie
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
09:30am, Friday, 19'th Sep 2025
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
01:20pm, Wednesday, 17'th Sep 2025
AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).
